TipRanks
Advertisement
Advertisement
Clearmind Medicine announces Yale IRB approval of Parts B, C of CMND-100 trial
PremiumThe FlyClearmind Medicine announces Yale IRB approval of Parts B, C of CMND-100 trial
11d ago
Clearmind Medicine to acquire 51% stake in Charging Robotics
Premium
The Fly
Clearmind Medicine to acquire 51% stake in Charging Robotics
15d ago
Psychedelic: Clearmind initiates Phase IIa of CMND-100 trial
Premium
The Fly
Psychedelic: Clearmind initiates Phase IIa of CMND-100 trial
16d ago
Psychedelic: Definium’s LSD-based pill meets endpoints in GAD study
PremiumThe FlyPsychedelic: Definium’s LSD-based pill meets endpoints in GAD study
1M ago
Clearmind Medicine reports MEAI development program permeation study results
Premium
The Fly
Clearmind Medicine reports MEAI development program permeation study results
1M ago
Psychedelic: Compass Pathways, GH Research report quarterly earnings
Premium
The Fly
Psychedelic: Compass Pathways, GH Research report quarterly earnings
1M ago
Psychedelic: PharmAla enters license agreement with Jupiter Neurosciences
PremiumThe FlyPsychedelic: PharmAla enters license agreement with Jupiter Neurosciences
2M ago
Clearmind files psychedelic patent application with Hong Kong Patent Office
Premium
The Fly
Clearmind files psychedelic patent application with Hong Kong Patent Office
2M ago
Clearmind reports positive retention results for intranasal formulation of MEAI
Premium
The Fly
Clearmind reports positive retention results for intranasal formulation of MEAI
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100